Is Pfizer Inc. a Buy?
Pfizer Inc. (NYSE: PFE) shares have risen around 12% this year, in step with the iShares US Pharmaceuticals index. With talk of another spinoff and strong sales growth, this big pharma stock looks like a buy on the surface. Let's look a little closer at these reasons to buy Pfizer -- plus a big reason to be nervous -- and see if it still has room to run.
Rumors that Pfizer might cleave off its consumer-healthcare business into a separate company are beginning to materialize. The company hasn't made any commitments yet, but management officially disclosed it's exploring options for popular over-the-counter brands that could take the form of a spinoff.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
€135.74
-0.750%
The stock is one of the favorites of our community with 33 Buy predictions and 1 Sell predictions.
With a target price of 195 € there is a positive potential of 43.66% for Johnson & Johnson compared to the current price of 135.74 €.
